Xavier said that patients are often reluctant to quit smoking because they are fearful that they will gain weight. By adding ...

New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...

Treating nicotine addiction with glucagon-like peptide 1 receptor agonists is associated with less weight gain compared with ...

Pepsi's slump is mainly due to aggressive price hikes and high T-bond yields, not diworsification or health trends.

Shop till you drop: Could Trump upend, reset the age of the insatiable American consumer?

In recent years, Kessler has lost considerable weight himself with the help of the new GLP-1 drugs. He describes his weight ...

And since GLP-1s come with side effects including fatigue, digestive difficulties, and loss of muscle, products to address ...

GLP-1 receptor agonists are associated with improvements in restrained eating, emotional eating behavior, QOL.

The popularity of GLP-1 drugs has insurance companies scrambling to satisfy consumer access while reining in exorbitant costs ...

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still ...

New research presented May 17 at the American Psychiatric Association's Annual Meeting shows that GLP-1 receptor agonists may ...

The recent decision by some US states to cover glucagon-like peptide-1 (GLP-1) agonists for obesity treatment marks a shift ...